Study Conducted Examining Additional Treatment of Chronic Hepatitis C

Posted on Jan 29, 2010

There is no question that chronic hepatitis C virus (HCV) can significantly impact a patient's life.  Hepatitis C is believed to be the most serious of all the hepatitis viruses.  It attacks the liver and causes inflammation.  The American Family Physician journal has referred to this virus as, the most common chronic blood-borne infection in the United States." 

Researchers in Italy recently looked into a revised treatment option for HCV.  Currently, chronic hepatitis C is treated with pegylated-interferon (PEG-IFN) and ribavirin, which has proved to be effective in about 50 to 60 percent of HCV cases.  During the study, the Italian research team assessed the safety of including ketoprofen, a non-steroidal anti-inflammatory drug, with the pegylated-interferon.  Researchers observed the impact this revision had on patients. 

According to the study's findings, which were published in the December 21, 2009 issue of the World Journal of Gastroenterology, the addition of the non-steroidal anti-inflammatory drug did produce good results.  The authors of the study have suggested that a larger study be done to continue to review the effectiveness of this three-drug combination. 

If you have been diagnosed with chronic hepatitis C virus, you may be entitled to disability insurance benefits.  Contact a Miami disability attorney at the law firm of J.P. Gonzalez-Sirgo at 305-461-1095 or toll free at 866-71-CLAIM for more information.

Read More About Study Conducted Examining Additional Treatment of Chronic Hepatitis C...